Cargando...
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However,...
Gardado en:
| Publicado en: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918267/ https://ncbi.nlm.nih.gov/pubmed/27508178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S45040 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|